Gibson Dunn Advises Apogee Therapeutics on $402.5 Million Offering of Common Stock
Firm News | March 26, 2026
Gibson Dunn represented Apogee Therapeutics, Inc. in a public offering of common stock that generated aggregate gross proceeds of approximately $402.5 million to Apogee.
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), Chronic Obstructive Pulmonary Disease (COPD) and other I&I indications.
Gibson Dunn regularly advises clinical-stage biotechnology companies on capital markets transactions in the life sciences sector.
The Gibson Dunn team included Ryan Murr, Branden Berns, Melanie Neary, Candice Johnson, Jasmine Vitug, and Anika Gidwani.